SecBot SecBot
8-K ·Filed May 6, 2026

LIVN

LivaNova PLC
BULLISH
Impact 8/10
Horizonweeks Processed6mo ago SEC0001639691-26-000031
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The combination of a strong Q1 beat, raised full-year guidance, and FDA approval for the aura6000 OSA system creates a powerful catalyst. The OSA market entry with a differentiated device (no contraindication for complete concentric collapse) could drive significant long-term growth. Monitor the upcoming conference call for initial commercialization plans and reimbursement strategy for aura6000.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$66.26
T+0 close · May 6, 2026 · via day close
Latest settled
+20.95%
T+60 · $80.14
Vs SPY
+18.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $66.26entry
  2. T+1 · 6mo ago +7.04%α +7.37% · $70.93
  3. T+5 · 6mo ago +8.29%α +7.15% · $71.75
  4. T+20 · 6mo ago +7.65%α +4.87% · $71.33
  5. T+60 · 4mo ago +20.95%α +18.89% · $80.14

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beating consensus of $346.1M. Adjusted diluted EPS of $0.98 exceeded the consensus estimate of $0.90 by 8.9%. The company raised full-year 2026 guidance: revenue growth raised 100bps to 7-8% constant-currency and adjusted EPS raised $0.05 to $4.20-$4.30. Additionally, the FDA granted premarket approval for the aura6000 System for obstructive sleep apnea, a significant new product catalyst.

Key Financial Metrics

EPS
$0.98
est $0.90 · +8.9%
Revenue
$362.3M
est $346.1M · +4.7% · +14.3% YoY
Rating
strong beat
Guidance
7.0% to 8.0% constant-currency growth
raised
Free Cash Flow
$3.8M
Gross Margin
67.3%

Key Facts

  • Q1 2026 revenue $362.3M, +14.3% reported / +11.1% constant-currency YoY, above $346.1M consensus
  • Q1 2026 adjusted diluted EPS $0.98, vs $0.90 consensus (beat by 8.9%)
  • Raised FY2026 revenue growth guidance to 7.0%-8.0% constant-currency (from 6.0%-7.0%)
  • Raised FY2026 adjusted EPS guidance to $4.20-$4.30 (from $4.15-$4.25)
  • FDA premarket approval received for aura6000 System for moderate-to-severe obstructive sleep apnea
  • Cardiopulmonary revenue +18.3% reported (+14.0% constant-currency); Neuromodulation +9.3% reported (+7.6% constant-currency)
  • Adjusted operating income $71.1M, up from $64.6M in Q1 2025
  • Adjusted free cash flow $3.8M in Q1 2026

Financial Impact

Revenue beat of ~$16.2M vs consensus; EPS beat of $0.08 vs consensus; guidance raised for both revenue and EPS

revenueepsguidance

Risk Factors

  • OSA market entry is still early-stage; commercialization and reimbursement timelines uncertain
  • GAAP operating income declined to $41.5M from $48.6M due to higher R&D spending ($58.7M vs $37.9M) for OSA investments
  • Adjusted free cash flow was only $3.8M, down from prior periods, though this is seasonally low
  • 3T Heater-Cooler litigation and SNIA environmental liabilities remain overhangs

Market Snapshot

Exchange
Nasdaq
Sector
Electromedical & Electrotherapeutic Apparatus
Analyst Consensus
76% bullish (17 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001639691-26-000031
Document: livn-20260506.htm0001639691-26-000031
Document: 0001639691-26-000031-index-headers.html0001639691-26-000031
Document: 0001639691-26-000031-index.html0001639691-26-000031
Document: 0001639691-26-000031.txt0001639691-26-000031
8-K Data (Synthetic)0001639691-26-000031

Track record

10 reports on LIVN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 12, 20264d ago 144 Neutral 2/10 Entry $91.32 Now $92.44 +1.23% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $90.98 Now $92.44 +1.60% settles Feb 9
  3. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $91.14 Now $92.44 +1.43% settles Feb 3
  4. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $94.19 Now $92.44 −1.86% settles Feb 2
  5. Sep 14, 20269w ago Insider Cluster Neutral 2/10 Entry $79.47 Now $92.44 +16.32% settles Dec 9
  6. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $78.93 Now $92.44 +17.12% settles Dec 3
  7. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $78.15 to $81.52 Now $92.44 +18.29% ▲ +4.32% +4.13% vs SPY
  8. May 6, 202627w ago 8-K Bullish 8/10 Viewing Entry $66.26 to $80.14 Now $92.44 +39.51% ▲ +20.95% +18.89% vs SPY
  9. Apr 29, 202628w ago DEFA14A Neutral 2/10 Entry $58.92 to $78.19 Now $92.44 +56.89% ▲ +32.71% +28.59% vs SPY
  10. Feb 25, 202637w ago 8-K Bullish 7/10 Entry $70.29 to $73.71 Now $92.44 +31.51% ▲ +4.87% −2.08% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026